Results 201 to 210 of about 24,701 (248)

Sexual behaviour among women using intramuscular depot medroxyprogesterone acetate, a copper intrauterine device, or a levonorgestrel implant for contraception: Data from the ECHO randomized trial. [PDF]

PLoS One
Hofmeyr GJ, Singata-Madliki M, Batting J, Steyn P, Thomas KK, Issema R, Beesham I, Mbatsane E, Morrison C, Deese J, Smit J, Philip N, Palanee-Phillips T, Reddy K, Onono M, Mastro TD, Baeten JM, Evidence for Contraceptive Options and HIV Outcomes (ECHO) Trial Consortium.   +17 more
europepmc   +1 more source

Investigation of the underlying molecular mechanisms of immune modulation by the contraceptive Medroxyprogesterone acetate (MPA) on immune responses to mycobacteria

, 2014
Lizaan Ehlers
openalex   +1 more source

Medroxyprogesterone acetate for uterine shrinkage.

South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde, 1979
openaire   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Anaphylaxis From Medroxyprogesterone Acetate

Obstetrics & Gynecology, 2004
More than 30 million women in more than 90 countries use depot medroxyprogesterone acetate as an injectable contraceptive agent, and it is thought to be very safe. However, it should be recognized that serious and potentially life-threatening adverse effects can occur.A 40-year-old para 2 went into anaphylactic shock after receiving 150 mg of depot ...
Daniel O, Selo-Ojeme, Amna, Tillisi, Christopher C, Welch   +2 more
openaire   +2 more sources

IMMUNOSUPPRESSION WITH MEDROXYPROGESTERONE ACETATE

Transplantation, 1968
The immunosuppressive effects of MPA (medroxyprogesterone acetate) were tested in clinical studies with laboratory dogs and rabbits. The laboratory procedures employed in the studies are explained and results are tabulated and graphed. 2 microscopic photographs illustrate the observed effects.
J G, Turcotte, R F, Haines, G L, Brody, T J, Meyer, S A, Schwartz   +4 more
openaire   +2 more sources

Medroxyprogesterone acetate in human serum

Journal of Steroid Biochemistry, 1981
Medroxyprogesterone acetate (MPA) exists in blood both in the unconjugated and in the conjugated state. The mean concentration of MPA obtained after enzymic hydrolysis of the conjugated fraction was 82% of that in the unconjugated fraction. The conjugate appears to be mainly a glucuronide since solvolysis released only small amounts of MPA. Metabolites
M, Mathrubutham, K, Fotherby
openaire   +2 more sources

Depot Medroxyprogesterone Acetate

2020
Depot medroxyprogesterone acetate (DMPA) is an injectable progestin-only contraceptive administered every 13 weeks. DMPA is an extremely effective contraceptive agent when used consistently. With typical use, approximately 6 out of 100 women will become pregnant in the first year of use, reflecting that some users do not return for repeat injections ...
Deanna C. McCullough, Kathryn M. Eraso, Andrew M. Kaunitz   +2 more
openaire   +1 more source

Medroxyprogesterone acetate therapy in hirsutism

British Journal of Dermatology, 1985
In a pilot study, 26 hirsute females were treated with medroxyprogesterone acetate (MPA). We used an ointment containing 0.2% MPA in 13 patients, subcutaneous injection of MPA into the hairy areas of the face in five patients and intramuscular injection of low doses of MPA in 13 patients, each for an average duration of 16 weeks.
J B, Schmidt, J, Huber, J, Spona
openaire   +2 more sources